Founder, Chair, and CEO of Lysogene, Ms. Karen Pignet-Aiach is also the mother of a child with MPS IIIA.

Dr. Ralph Laufer is responsible for Lysogene’s scientific activities.

Dr. Marie Deneux is in charge of defining and executing the regulatory strategy for the development and registration…

Dr. Mark Plavsic is responsible for Lysogene’ s manufacturing strategy and CMC operational development.

Dr. Sophie Olivier is responsible for clinical development.

Chief Patient Access Officer Ms. Samantha Parker is Head of Lysogene’s Patient and Policy Affairs.

Dr. Michaël Hocquemiller is in charge of the non-clinical development of Lysogene’s gene therapy products including…